Hand Dermatitis

Researchers are conducting a phase 2b, multicenter, randomized, double-blind, placebo-controlled study to evaluate camoteskimab in adults with moderate-to-severe atopic dermatitis. The study includes both treatment-naive participants and those who have had an inadequate response to previous biologic therapies, aiming to assess the effectiveness and safety of camoteskimab for this condition. The study has two parts. In Part 1, lasting 24 weeks, participants are randomly assigned to receive one of three doses of camoteskimab or a placebo, all given by subcutaneous injection. In Part 2, which is an extension period, all participants will receive camoteskimab. This design allows comparison of different doses and the placebo before all receive the active treatment. Participants will undergo regular assessments including evaluation of eczema severity, body surface area affected, and itch intensity using specific scales like the Eczema Area and Severity Index EASI and Peak Pruritus Numerical Rating Scale PP-NRS. Researchers will monitor changes from baseline over 24 weeks. Safety and adherence will be closely followed throughout the study, which is planned to continue until April 2028.

Researchers are evaluating SHR-1894, a drug administered by single subcutaneous injection, in healthy adults aged 18 to 45 years. This Phase I clinical trial aims to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of SHR-1894. The study compares different doses of SHR-1894 injection with a placebo injection under controlled conditions. Participants will be randomly assigned to receive either SHR-1894 injection at varying doses or a placebo injection. Both participants and researchers will be unaware of the assigned treatment to ensure unbiased results. The study includes a follow-up period lasting up to 85 days to monitor effects and drug behavior in the body. During the trial, participants will undergo physical exams, vital sign checks, ECGs, chest X-rays, abdominal ultrasounds, and laboratory tests before and after treatment. Researchers will track any adverse events, measure drug concentrations in the blood over time, and assess immune responses. The total participation time covers screening, dosing, and monitoring visits spread across nearly three months.

Researchers are evaluating how the combined use of transcranial direct current stimulation tDCS and action observation therapy AOT may help improve hand motor recovery in people who have had a stroke. This study focuses on understanding the brain mechanisms involved when these two therapies are used together, as both have shown promise separately for stroke rehabilitation. The trial is a randomised controlled study involving 60 participants with chronic stroke from Sabah, Malaysia. Participants will be randomly assigned to one of three groups one group will receive active anodal tDCS with AOT, another will receive sham placebo tDCS with AOT, and the third will receive active tDCS alone. The treatment involves 10 sessions over two weeks in a clinic, where tDCS is applied for 20 minutes and AOT or control videos are watched for 30 minutes during each session. After the clinic phase, participants will continue home-based AOT or control video practice for 30 minutes a day, five days a week, for eight weeks. During the 10-week study, participants will attend outpatient sessions monitored by a physiotherapist to ensure proper participation and will be assessed at baseline, after two weeks, and at the end of 10 weeks. Researchers will measure changes in brain motor pathways using motor evoked potentials MEPs and evaluate clinical hand function using standard tests. Participant activity levels will be tracked using a perceived exertion scale, and safety and compliance will be closely monitored throughout the study.

Researchers are investigating chronic hand eczema CHE and atopic dermatitis AD in adults with moderate to severe forms of these conditions, as well as in healthy volunteers. The study aims to characterize differences in skin features and molecular markers over time using noninvasive methods. It also evaluates how disease severity relates to lifestyle, occupation, smoking, and quality of life. Participants include adults with moderate to severe CHE, those with moderate to severe AD, and healthy adults. The study uses noninvasive imaging and molecular techniques to assess skin changes and collects samples such as plasma, serum, blood, stool, and skin materials for long-term analysis. An optional genetic analysis called tape stripping may be performed on CHE participants. During the 12-month study, participants undergo assessments of skin morphology and molecular signatures, alongside evaluations of quality of life and disease impact. Samples are stored for up to 10 years to support further research. Participants are monitored for changes in skin condition and lifestyle effects, with data compared across the groups including healthy controls.

Researchers are collecting various samples from adults with different inflammatory skin diseases as well as healthy volunteers to better understand these conditions. The study aims to analyze these samples using methods like biomarker testing and gene expression profiling to gain molecular insights into skin diseases such as acne, atopic dermatitis, chronic hand eczema, hidradenitis suppurativa, palmoplantar pustulosis, and psoriasis. Participants include healthy adults and adults diagnosed with specific skin conditions aged 18 years or older, with acne subjects limited to ages 18 to 45 years. The study involves collecting blood, oral, hair, skin using tape strips, biopsies, or scrapings, skin surface materials, drainage fluid, and stool samples. These samples will be used for various analyses to explore biomarkers and gene expression. During the study, participants will provide the different biological samples on Day 1, which will be analyzed for untargeted biomarkers and gene expression profiles. The researchers will monitor these molecular markers to understand skin disease characteristics. Participants must consent to the procedures and be available for the study duration. The study is observational, with no treatment given, and focuses on sample collection and molecular data gathering.

This research evaluates a virtual reality VR intervention designed to teach handwashing skills to junior secondary students in Hong Kong. The study aims to see if the VR game improves handwashing technique and promotes lasting hygiene habits. It addresses important questions about how VR-based education may enhance learning and sustain behavior changes compared to other educational methods. Participants will be randomly divided into three groups for two educational sessions over a 9-month school year. One group will have two VR game sessions focused on a 7-step handwashing method, another group will have one VR session and one video session about hand hygiene, and the third group will have two VR sessions unrelated to hand hygiene plus a handwashing poster. The VR game includes guided practice and challenge modes with hand-motion tracking. During the study, participants will play the VR game or attend videoVR activities, perform handwashing with fluorescent lotion for UV imaging to assess cleanliness, and complete questionnaires on knowledge, habits, attitudes, and VR experience. Hand-imaging data will be collected before and after the interventions to measure handwashing performance and sustained effects. Surveys will be conducted at several points to evaluate behavioral factors and hygiene knowledge over the study period.

Researchers are studying how different treatments for atopic dermatitis, a chronic skin condition sometimes complicated by Staphylococcus aureus infections, affect the types and amounts of bacteria on the skin. This Phase 2 trial involves both patients with moderate to severe atopic dermatitis and healthy volunteers, aiming to understand the impact of antimicrobial treatments on the skin microbiome over time. Participants are assigned to various treatment groups receiving antibiotics such as cephalexin, doxycycline, or trimethoprimsulfamethoxazole, alone or combined with dilute bleach bath treatments or placebos. The study includes randomized, placebo-controlled, and investigator-blinded antimicrobial treatments, with some participants undergoing long-term follow-up visits to assess how these treatments alter the skin microbiome. Throughout the one-year study, participants attend regular visits for physical exams, medical history reviews, and collection of skin samples, including possible biopsies. Researchers monitor changes in the skin bacteria, assess clinical responses, and evaluate antibiotic resistance patterns. Healthy volunteers may also be invited for a one-time follow-up beyond the study year to continue microbiome assessments.

Researchers are studying the skin compatibility of cosmetic products by testing for potential irritants and allergic reactions. This trial focuses on adults with skin conditions who undergo patch testing to identify whether cosmetics cause skin irritation or allergies. The study is led by Insel Gruppe AG, University Hospital Bern, and aims to assess the safety of new or reformulated cosmetics for people with dermatitis. Participants will receive a patch test where a cosmetic product is applied to their back to observe skin reactions. This procedure helps to detect allergic or irritant responses. The study does not use a control or placebo group and does not involve masking or blinding. During the study, participants will be monitored for positive skin reactions to the patch test over a period of four weeks. Researchers will track the number of patients showing allergic or irritant responses. Participants must avoid certain medications and skin treatments before testing and will be followed to ensure accurate results and safety throughout the trial.

Atopic dermatitis AD is a common, long-lasting inflammatory skin condition in children that causes itching and skin lesions, affecting quality of life. This research evaluates a hypnosis program as a possible new therapy to help manage AD symptoms. The study is a pilot randomized controlled trial designed to test the feasibility of hypnosis in children and teenagers with AD, addressing the need for alternative treatments due to challenges like chronicity and treatment costs. Participants will be divided into two groups one receiving a therapeutic education program alone, and the other receiving the same program combined with two standardized hypnosis sessions using a superhero costume technique. The hypnosis group will also practice self-hypnosis at home using an audio recording to reinforce the sessions. The study aims to assess how well this hypnosis program can be integrated into care for AD. During the study, researchers will monitor patient recruitment over 24 months and evaluate compliance with self-hypnosis at 1, 3, and 6 months after joining the study. They will also track patient satisfaction, dropout rates, parents impressions, improvements to the hypnosis program, and overall effectiveness at these intervals. The trial involves children aged 8 to 17 with mild to severe AD, and participation will include follow-up assessments at scheduled times.

Researchers are investigating the immune characteristics of chronic hand eczema in adults aged 18 to 65 years. This study aims to reveal new insights into the disease by comparing different types of chronic hand eczema, including endogenous forms like atopic dermatitis and idiopathic subtypes such as pompholyx and hyperkeratotic eczema, as well as exogenous forms such as allergic and irritant eczema. The goal is to identify immune cell groups and molecular markers that could lead to personalized treatments. The study uses advanced techniques called spatial transcriptomics and single-cell spatial proteomics to analyze skin biopsy samples from affected areas. Patients diagnosed with chronic hand eczema will have their disease severity assessed through validated scores and patch tests, followed by skin biopsies to confirm the diagnosis. These biopsies will undergo detailed genetic and protein analysis to map the immune landscape of the eczema. Participants will be involved for an average of two years during which the main measurement will be the spatial proteomics analysis of their skin samples. Throughout the study, severity scores like HECSI, DLQI, and itch scales will be used to evaluate the condition. The research team will monitor the immune profiles to understand disease mechanisms and potential targets for therapy, with no masking or blinding involved.